In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Merckle acquires Technilab Pharma

Executive Summary

Merckle has agreed to acquire Technilab Pharma (Montreal-based generics company) for $4.13 ($Cdn6.10) per share, a (pr)46% premium based on the market average, for a total of $54.7mm. Members of the Sabourin family, who owned about 65% of the outstanding shares, irrevocably tendered their shares in this transaction.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Generic Drugs
Deal Status
  • Final
Deal Type
  • Acquisition
    • Full Acquisition
    • Payment Includes Cash

Related Companies